Yale Cancer Center
Yale Cancer Center
New Haven, Connecticut, United States31 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07421167 | |
| A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07266428 | |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Metastatic Hormone-sensitive Prostate Cancer | Active, not recruiting | Phase 2 | 2026-10-09 | NCT06991556 | |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-10-09 | NCT04929223 | |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06084936 | |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT05789082 | |
| A Study of PHST001 in Advanced Solid Tumors | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, breast cancer, breast disorder, breast neoplasm, carcinoma, carcinosarcoma, central nervous system cancer, central nervous system neoplasm, cholangiocarcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, mixed neoplasm, neoplasm, nervous system disorder, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, sarcoma, skin disorder, uterine disorder | Recruiting | Phase 1 | 2026-10-05 | NCT06840886 | |
| IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 3 | 2026-10-01 | NCT07104032 | |
| A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cancer, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder | Recruiting | Phase 1 | 2026-09-29 | NCT07578571 | |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT06385080 | |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Carcinoma, Ductal, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast ductal adenocarcinoma, breast neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-09-23 | NCT07214532 | |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-18 | NCT03435796 | |
| The SUGAR Study; SBRT and Relugolix) for Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-09-14 | NCT06111781 | |
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-09-09 | NCT05968326 | |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-08-28 | NCT07029399 | |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium adenocarcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-08-21 | NCT05548296 | |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-18 | NCT05067140 | |
| A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-08-06 | NCT03862430 | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Recurrent Solid Tumors | Active, not recruiting | Phase 1 | 2026-07-28 | NCT06031441 | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-17 | NCT05306340 | |
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Adenomatous Polyps, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cronkhite-Canada syndrome, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, adenoma, classic familial adenomatous polyposis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, neoplasm, polyp | Recruiting | Phase 3 | 2026-06-02 | NCT06950385 | |
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | Urothelial Cancer | Active, not recruiting | Phase 3 | 2026-05-29 | NCT04223856 | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Carcinoma, Medullary, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Thyroid Cancer, Papillary, adenocarcinoma, breast disorder, breast neoplasm, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, central nervous system cancer, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant colon neoplasm, malignant endocrine neoplasm, medullary thyroid gland carcinoma, neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, papillary adenocarcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, thyroid gland disorder, thyroid tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-16 | NCT03157128 | |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, angiosarcoma, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, fibrolamellar hepatocellular carcinoma, gonadal disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, sarcoma, uterine disorder, vascular cancer | Active, not recruiting | Phase 1 | 2026-03-30 | NCT03860272 | |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-03-18 | NCT06153251 |